Amylyx Pharmaceuticals, Inc. 4

Co-CEO Joshua B. Cohen sold 30,464 shares of Amylyx Pharmaceuticals common stock on 2026-09-10 in automatic sales to cover taxes from PSU vesting, retaining 3.6M shares afterward.

On September 10, 2026, Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen sold an aggregate 30,464 shares of Amylyx Pharmaceuticals, Inc. common stock in two open market transactions at weighted average prices of $32.1557 and $33.1488 per share, totaling approximately $979,000 in value. According to the filing, these sales were executed automatically solely to satisfy tax withholding obligations related to the vesting of performance stock units and were not discretionary trades by Cohen. Following the transactions, Cohen continued to hold 3,613,123 shares of common stock directly, reflecting a substantial ongoing equity stake in the company.

Filing Facts

CIK

1658551

Ticker

AMLX

Form

4

Source Type

fda

Accession

0001193125-26-390507

Alert Tier

6